ORLANDO, FL, Aug. 04, 2022 (GLOBE NEWSWIRE) — Immune Therapeutics, Inc. (OTC PINK:IMUN) (“Immune” or “IMUN”), a specialty pharmaceutical company involved in the acquisition, development and commercialization of pharmaceutical and biotechnology products that have a short and well-defined path to market, is pleased to announce the appointment of Glen Farmer as Chief Financial Officer and Kelly Wilson as Chief Operating Officer. Mr. Farmer will replace Dr. Stephen Wilson who served as interim chief financial officer and is currently the company’s president, chief executive officer and director. Ms. Wilson will fill the vacant position of Chief Operating Officer.
Mr. Farmer has over 30 years of experience building and scaling finance, accounting and operations for start-up and development-stage businesses. He has held numerous senior financial positions in startups and large private and public sector companies across many industries. He was most recently Vice President and US Controller at iAnthus Capital Management, Inc., a public company with more than 1,000 employees and 42 consolidated subsidiaries. Prior to iAnthus, he held CFO positions at Croma Pharmaceuticals, Inc. and Primetime Life Sciences and was Controller and Senior Accountant at Avalon Pharmaceuticals.
Mr. Farmer holds a bachelor’s degree in accounting from the University of Maryland and an MBA with a concentration in finance from Mount St. Mary’s University. He joins Immune to oversee Immune’s global finance team. He will report directly to the CEO of Immune.
“Glen is a highly accomplished CFO who will bring a wealth of experience to Immune’s new leadership, including experience with public companies in corporate finance, corporate collaborations and licensing. Glen’s extensive experience in global finance and operations, as well as his track record with early-stage biotechnology companies, will be critical as Immune enters its next phase of growth and as we begin commercialization efforts, studies and clinical trials,” said Dr. Stephen Wilson, CEO of Immune. “On behalf of the entire Immune team, I welcome Glen and look forward to his contributions.”
In addition to the appointment of Mr. Farmer, Immune also announced the appointment of Kelly O’Brien Wilson as Chief Operating Officer. Ms. Wilson brings more than 25 years of leadership, technology and operations experience to Immune. She has held leadership and development roles with startups and large corporations in the private, public, and government sectors across multiple industries, including biotechnology, manufacturing, and computer software. She served as Chief Technology Officer and Chief Human Resources Officer at Immune from 2015-2020 and has experience managing many different business departments including Information Technology, Human Resources and Corporate Operations. . Ms. Wilson graduated with honors from the University of Central Florida with a master’s degree in systems design and a bachelor’s degree in English.
In this new role, Ms. Wilson will be responsible for overseeing the company’s major business units and subsidiaries and working directly with Immune’s international leadership by assisting with organization and country management functions. She will strive to maximize the potential of the company’s growing portfolio of products, most of which are in a combination of approved and growth phases.
Dr. Stephen Wilson, CEO, said, “Ms. Wilson’s prior experience with Immune places her in a unique position to expedite the leadership transition as the company implements its new strategy. With knowledge of past practices and experience in systems design, the responsibility of modernizing critical aspects of our organization to maximize our operational efficiency and improve resource allocation is a perfect fit for Ms. Wilson. On behalf of the entire Immune team, we welcome him to the company and look forward to a successful future.
This press release may contain information about our views on future expectations, plans and prospects that constitute forward-looking statements. All forward-looking statements are based on management’s beliefs, assumptions and expectations regarding Immune’s future economic performance, taking into account information currently available to it. These statements are not statements of historical fact. Although Immune believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, it cannot guarantee that its expectations will be achieved. Immune assumes no obligation to update any statements contained herein (including forward-looking statements), except as required by law. No assurance can be given that Immune will be successful in acquiring its acquisition targets. Forward-looking statements are subject to a number of factors, risks and uncertainties, some of which are not currently known to us, that may cause Immune’s actual results, performance or financial condition to be materially different. expectations of future results, performance or financial condition. Actual results may differ materially from the expectations discussed in the forward-looking statements. Factors that could cause actual results to differ materially from expectations include general industry considerations, regulatory changes, changes in local or national economic conditions and other risks set forth in the “Risk Factors” section included in our documents filed with the Securities and Exchange Commission.
The information provided in this press release is intended for general knowledge only and is not a substitute for professional medical advice or treatment for specific medical conditions. Always seek the advice of your physician or other qualified health care provider with any questions you may have regarding a medical condition. This information is not intended to diagnose, treat, cure or prevent any disease.
Dr. Stephen Wilson